CRISM Therapeutics (CRTX) Stock Overview
Develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CRTX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Top Community Narratives
Bright future for a healthy business - get in early!
CRISM Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.12 |
| 52 Week High | UK£0.29 |
| 52 Week Low | UK£0.08 |
| Beta | 0.48 |
| 1 Month Change | -11.32% |
| 3 Month Change | 17.50% |
| 1 Year Change | 23.68% |
| 3 Year Change | -95.68% |
| 5 Year Change | -95.10% |
| Change since IPO | -99.78% |
Recent News & Updates
Shareholder Returns
| CRTX | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 4.4% | -3.5% | 2.4% |
| 1Y | 23.7% | 18.1% | 20.5% |
Return vs Industry: CRTX exceeded the UK Biotechs industry which returned 13.8% over the past year.
Return vs Market: CRTX exceeded the UK Market which returned 17.9% over the past year.
Price Volatility
| CRTX volatility | |
|---|---|
| CRTX Average Weekly Movement | 13.4% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: CRTX's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: CRTX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Andrew Webb | www.crismtherapeutics.com |
CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs. Its lead product is ChemoSeed, an implantable biodegradable drug delivery technology for the delivery of chemotherapy directly into cancer tissues. The company also offers formulation and consultancy services.
CRISM Therapeutics Corporation Fundamentals Summary
| CRTX fundamental statistics | |
|---|---|
| Market cap | UK£6.08m |
| Earnings (TTM) | -UK£1.49m |
| Revenue (TTM) | UK£25.00k |
Is CRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRTX income statement (TTM) | |
|---|---|
| Revenue | UK£25.00k |
| Cost of Revenue | UK£7.00k |
| Gross Profit | UK£18.00k |
| Other Expenses | UK£1.51m |
| Earnings | -UK£1.49m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | 72.00% |
| Net Profit Margin | -5,952.00% |
| Debt/Equity Ratio | 0% |
How did CRTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/01 15:49 |
| End of Day Share Price | 2026/04/01 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CRISM Therapeutics Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lord Ashbourne | Edison Investment Research |
| Desmond Kilalea | RBC Capital Markets |